Oxidative Stress at the Crossroads of Aging, Stroke and Depression

Shao Anwen, Lin Danfeng, Wang Lingling, Tu Sheng, Lenahan Cameron, Zhang Jianmin

Table 4 Antidepressants in PSD treatment.

Antioxidants in PSD Clinical trials Outcomes fluoxetine FOCUS not support routine use of fluoxetine in preventing PSD or promoting function recovery fluoxetine/paroxetine meta-analysis of 12 trials fluoxetine is the worst choice for PSD treatment; paroxetine is the best drug in terms of efficacy and acceptability meta-analysis of 20 RCTs citalopram has similar efficacy and safety as other SSRIs but acts faster than them fluoxetine FLAME exhibit a positive connection between motor recovery escitalopram Cochrane review escitalopram is the best tolerated SSRI, followed by sertraline and paroxetine for PSD escitalopram RCT not take effects on depressive symptoms; diarrhea is more likely to occur escitalopram RCT effective at decreasing the incidence of depression in nondepressed patients Citalopram RCT safe for patients with acute ischemic stroke Citalopram RCT different effects in different stages of PSD citalopram RCT SSRI treatment is well tolerated and beneficial in PSD SSRI registry-based score-matched follow-up study pre-stroke SSRI use increases risk of the hemorrhagic stroke; no increased stroke severity and mortality ischemic stroke milnacipran RCT milnacipran prevents post-stroke depression; safe to use without serious adverse events